Global Top 10 Most Used PD-(L)1 Drugs: Reshaping the Landscape of Cancer Immunotherapy

With the advent of the immunotherapy era, PD-L1 drugs have become a focal point for cancer patients and medical practitioners. This article provides an in-depth analysis of the world's most used PD-L1/PD-1 drug list, covering mechanisms of action, clinical effects, and applicable populations. DengyueMed sorts out these "star drugs" that are rewriting the pattern of cancer treatment for you.

What Are PD-L1 Drugs?

PD-L1, fully known as "Programmed Death-Ligand 1," is a "disguise protein" used by tumor cells to evade attacks from the immune system. When it binds to the PD-1 receptor on the surface of immune T cells, it sends a "don't attack me" signal to the immune cells.

The essence of PD-L1 drugs is a kind of "immune unlocking key." By blocking the binding of PD-L1 and PD-1, it tears off the tumor's disguise, allowing T cells to re-identify and attack cancer cells. Unlike chemotherapy, which directly kills cells, it fights cancer by activating the body's own immune system, resulting in fewer side effects and more sustained efficacy.

Global Top 10 PD-L1/PD-1 Drugs List and Core Advantages

The following 10 drugs not only represent the highest level of current cancer immunotherapy but also drive the transformation of global tumor treatment concepts.

Summary and Outlook

Although PD-L1 drugs have brought revolutionary breakthroughs, they are not a "panacea." Currently, only a portion of patients can benefit from them. Doctors typically screen suitable candidates by detecting biomarkers such as PD-L1 expression levels in tumor tissues and tumor mutation burden (TMB). Additionally, immune-related adverse reactions require close monitoring, with early detection and intervention to ensure treatment safety.

With the exploration of combination therapies such as dual immunotherapy and immunotherapy plus targeted therapy, the application scenarios for PD-L1 drugs will continue to expand. In the future, with the rise of novel therapies like bispecific antibodies and ADC drugs, the application scenarios for PD-(L)1 inhibitors will keep expanding—from neoadjuvant/adjuvant treatment for early-stage cancers to combined multi-modal therapies. They will continue to play a core role in the long-term battle against cancer, bringing more possibilities for cures to patients worldwide.